Back to results
US 2023/0146841 A1Published application
Tnfaip3 as a biomarker for autoimmune diseases
AssigneeThe Brigham and Women's Hospital, Inc.
InventorTanuja Chitnis
Life of this patent
Estimating the term…
Abstract
Aspects of the present disclosure relate to methods for detecting tumor necrosis factor alpha-induced protein 3 (TN-FAIP3) in a sample from a subject having or at risk for myelin oligodendrocyte glycoprotein antibody associated diseases (MOG-AAD) or a relapse thereof.
Claims20
A method for analyzing a sample, the method comprising:
- providing a sample from a subject, and
- detecting tumor necrosis factor alpha-induced protein 3 (TNFAIP3) in the sample.
A method of diagnosing a subject as having myelin oligodendrocyte glycoprotein antibody associated diseases (MOG-AAD) or a relapse thereof, the method comprising:
- providing a sample from the subject,
- detecting a level of tumor necrosis factor alpha-induced protein 3 (TNFAIP3) in the sample;
- comparing the level of TNFAIP3 in the sample to a reference level, and
- diagnosing a subject as having MOG-AAD or a relapse thereof when the level of TNFAIP3 in the sample is lower than the reference level.
1 more element
Dependencies are inferred from the claim text.